Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Receivables (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Receivables for 11 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 27.87% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 27.87% increase, with the full-year FY2025 number at $1.1 million, up 27.87% from a year prior.
  • Receivables was $1.1 million for Q4 2025 at Cartesian Therapeutics, up from $722000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $35.5 million in Q2 2024 to a low of $354000.0 in Q2 2025.
  • A 5-year average of $8.2 million and a median of $7.0 million in 2022 define the central range for Receivables.
  • Peak YoY movement for Receivables: soared 451.41% in 2024, then tumbled 99.0% in 2025.
  • Cartesian Therapeutics' Receivables stood at $9.9 million in 2021, then decreased by 1.57% to $9.8 million in 2022, then decreased by 9.29% to $8.9 million in 2023, then crashed by 90.15% to $872000.0 in 2024, then increased by 27.87% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Receivables are $1.1 million (Q4 2025), $722000.0 (Q3 2025), and $354000.0 (Q2 2025).